home About Roche Patients Diagnostics Press room Roche Careers R&D Transparency Press room 2017 one two 3 ... 4 of 4 Madrid, September 21, 2017 Roche Farma and Fundación ONCE join forces for the labor integration of people with disabilities Roche Farma and Inserta Empleo, the ONCE Foundation entity for training and employment, have joined forces with the aim of promoting access to the labor market for people with disabilities. To do this, they have launched 'Volunteers for Integration', a project that has been presented today in Madrid during a conference, co-financed by the European Social Fund, in which both entities have formalized their collaboration, which began earlier this year . Madrid, 11 September 2017 Roche remains the most sustainable company in the healthcare sector according to the Dow Jones indices This is the ninth consecutive year that Roche has been recognized as the leading sustainability company in the "Pharmaceutical Industry, Biotechnology and Life Sciences" group of the Dow Jones Sustainability Indices (DJSI). These indices analyze the economic, social and environmental aspects of companies and are the reference for investors who apply sustainability criteria in the selection of their portfolios. Madrid, 11 September 2017 New data on Alectinib show its efficacy in first-line ALK + non-small cell lung cancer and in previously treated patients Roche today announced the results of the global phase III ALUR study in previously treated ALK + non-small cell lung cancer (NSCLC) and an update of the data of the phase III ALEX study that compares, in the first line, the efficacy of the activity in the system central nervous system (CNS) of Alectinib versus the standard of care, crizotinib. The data were presented at the Congress of the European Society of Medical Oncology (ESMO, for its acronym in English) held in Madrid. Madrid, 05 September 2017 Roche Presents Study Data with 18 of its Licensed and Experimental Therapies at ESMO 2017 Roche announced today that it will present new results of its studies with 18 licensed and experimental therapies during the Congress of the European Society of Medical Oncology (ESMO) in Madrid from 8 to 12 September. New features include data from several phase III studies with company drugs, including Vemurafenib (Zelboraf ® ) and Alectinib (Alecensa ® ); advances in its program for developing immunotherapy against multiple types of tumors, as well as new findings on the biology of cancer that will help to better understand this highly complex disease. Basel, July 24, 2017 Atezolizumab receives positive opinion from the CHMP for a specific type of metastatic lung cancer and two types of metastatic bladder cancer Roche has announced that the European Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for the use of Atezolizumab as monotherapy for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) in patients previously treated with chemotherapy. People with the activated EGFR or ALK positive mutation should also receive targeted therapy before being treated with atezolizumab. This positive opinion has been based on the results of the phase III OAK and phase II POPLAR studies.. The CHMP has also recommended the use of the drug as monotherapy for adults with locally advanced or metastatic urothelial carcinoma (mCU) who have previously been treated with platinum chemotherapy or who are not candidates for cisplatin chemotherapy. This positive opinion was based on the results of the phase III study IMvigor211 and cuts 1 and 2 of the phase II study IMvigor210 . Madrid, 20 July 2017 Australian Drug Agency Approves Ocrelizumab for Cluster and Primary Progressive Multiple Sclerosis Roche ha anunciado que la Agencia Australiana del Medicamento (Australian Therapeutic Goods Administration, TGA por sus siglas en inglés) ha autorizado Ocrelizumab como tratamiento para dos formas de esclerosis múltiple: la Esclerosis Múltiple en Brotes (EMR) y la Esclerosis Múltiple Primaria Progresiva (EMPP). Se trata de la segunda aprobación que recibe este fármaco para ambas indicaciones, tras la decisión adoptada por la FDA el pasado mes de marzo. Las solicitudes de comercialización de Ocrelizumab están en proceso de revisión en más de 50 países de todo el mundo, incluyendo Europa, Latinoamérica y Oriente Medio. Madrid, 17 julio 2017 El proyecto ‘STOP FUGA DE CEREBROS’ entrega la beca en la Comunidad Valenciana a la investigadora Aitana Braza Hoy se ha celebrado la entrega de la beca del proyecto ‘Stop Fuga de Cerebros’, iniciativa lanzada por Roche España con el objetivo de retener el talento de investigadores españoles que muchas veces se ven obligados a salir del país por la falta de recursos para desarrollar sus proyectos. Madrid, 13 julio 2017 El proyecto ‘STOP FUGA DE CEREBROS’ entrega su primera beca en Aragón a la investigadora Beatriz Tavira Hoy se ha celebrado la entrega de la primera beca del proyecto ‘Stop Fuga de Cerebros’, iniciativa lanzada por Roche España con el objetivo de retener el talento de investigadores españoles que muchas veces se ven obligados a salir del país por la falta de recursos para desarrollar sus proyectos. Basilea, 13 julio 2017 The New England Journal of Medicine (NEJM) publica los resultados positivos fase III de Emicizumab frente a la hemofilia A Roche ha anunciado hoy nuevos datos positivos de sus dos estudios fase III en Hemofilia A, HAVEN 1 y HAVEN 2. Asimismo, ha comunicado que la revista científica The New England Journal of Medicine (NEJM) ha publicado los nuevos datos del fase III HAVEN 1 presentados en el congreso, que evalúa la administración subcutánea semanal de Emicizumab en profilaxis (preventivo) en adultos y adolescentes con hemofilia A e inhibidores del factor VIII. Amsterdam, 28 junio 2017 Ocrelizumab reduce significativamente la progresión de la esclerosis múltiple en sus formas en brotes y primaria prorgesiva Roche announced new data from a subsequent analysis of the phase III clinical development program with Ocrelizumab during the III Congress of the European Academy of Neurology that is being held in Amsterdam until June 27. These new results reinforce the drug's efficacy in the relapsing (EMR) and primary progressive forms of multiple sclerosis (PPMS) compared to other available therapies. one two 3 ... 4 of 4 Press releases News 2017 News 2016 News 2015 2014 news News 2013 Contact information Roche Pharma spain.comunicacion@roche.com Roche Diagnostics barcelona.webmaster@roche.com © 2017 Roche Farma, SA © 2017 Roche Diagnostics, SL Legal notice and privacy policy Cookies policy The information contained in this website is aimed at healthcare professionals, including those who prescribe / dispense drugs in Spain. X Roche uses cookies to collect personal data related to you and your browsing activity in order to improve the website and your browsing experience. For more information about our use of cookies and how you can indicate your preferences regarding the use of cookies, see ourCookies policy. If you continue browsing, we will consider that you accept their use. To accept